Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
32 Leser
Artikel bewerten:
(0)

BIO-Europe 2015 is a virtual barometer of drug development future market

An estimated 4,000 licensing opportunities to be on offer at event

CARLSBAD, California and MUNICH, Oct. 26, 2015 /PRNewswire/ --BIO-Europe® 2015 international life science partnering conference, held in Munich, Germany, November 2-4, 2015, expects over 3,300 delegates representing investors, biotech innovators and pharmaceutical executives from the global drug development industry.

"BIO-Europe is a valuable forum for us to meet a wide range of companies," said Jeremy Springhorn, PhD, Partner, Corporate Development at Flagship Ventures. "We understand the importance of strategic partnerships, and BIO-Europe continues to be a productive event for building relationships."

"At Bristol-Myers Squibb, we have long since recognized that innovation happens everywhere and partnering has been an important part of our strategy for decades," said Mohamed Ragab, VP Oncology Search and Evaluation, Bristol-Myers Squibb. "We are always in search of partners who can help us continue to advance the science of immuno-oncology, and BIO-Europe enables us to evaluate a large number of companies and potential licensing opportunities in a short amount of time."

Another big draw of BIO-Europe 2015 will be the high-caliber presenting companies attending. Over 150 biotech, midsize pharma, next generation and academic-phase companies are expected to present and an estimated 4,000 licensing opportunities will be on offer at the event.

Leading pharmaceutical companies sponsoring the event send teams of scouts to BIO-Europe to engage with new and innovative products, ideas and companies. Large drug development firms in attendance and ready to partner include:

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • GSK
  • Johnson & Johnson
  • Lilly
  • Merck
  • MSD
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi
  • Takeda, and more.

BIO-Europe registration numbers are already up and expected to surpass last year's edition. The 2014 event featured 17,902 one-to-one partnering meetings. Over 3,200 delegates from 1,772 companies representing 54 countries attended. There were 162 company presentations with 4,032 licensing opportunities on offer, and 98 exhibitors at the event.

BIO-Europe registration information is available online.

Additional links and information:

Follow BIO-Europe 2015 on Twitter: @EBDGroup (hashtag: BEU15).

Online Press Kit service for BIO-Europe 2015 is available from PR Newswire to enhance your public relations efforts.

About EBD Group

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group's conferences are run with the support of leading corporations and international trade associations and include:

  • BIO-Europe® andBIO-Europe Spring®, Europe's largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
  • BioPharm America', the fastest growing partnering event in North America
  • Biotech Showcase', a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors
  • BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
  • ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio® Group
  • Biolatam®, facilitating partnering among global life sciences executives in Latin America's vibrant life science hubs

EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.

EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com.

© 2015 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.